Literature DB >> 28521509

The cost of accessing infant HIV medications and health services in Uganda.

Julie N Bergmann1,2, Rhoda K Wanyenze3, Jamila K Stockman1.   

Abstract

Patient costs are a critical barrier to the elimination of mother to child HIV transmission. Despite the Ugandan government providing free public HIV services, infant antiretroviral (ARV) prophylaxis coverage remains low (25%). To understand costs mothers incur in accessing ARV prophylaxis for their infants, we conducted a mixed methods study to quantify and identify their direct costs. We used cross-sectional survey data and focus group discussions from 49 HIV-positive mothers in Uganda. Means and standard deviations were calculated for the direct costs (e.g., transportation, caretaker, services/medications) involved in accessing infant HIV services. The direct cost of attending HIV clinic visits averaged $3.71 (SD = $3.52). Focus group discussions identified two costs hindering access to infant HIV services: transportation costs and informal service charges. All participants reported significant costs associated with accessing infant HIV services - the equivalent of 2-3 days' income. To address transportation costs, community and home care models should be explored. Additionally, stricter policies and oversight should be implemented to prevent informal HIV service charges.

Entities:  

Keywords:  HIV-exposed infants; Patient costs; direct costs; mother to child transmission of HIV; sub-saharan Africa

Mesh:

Substances:

Year:  2017        PMID: 28521509     DOI: 10.1080/09540121.2017.1330531

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  1 in total

1.  Does universal health coverage reduce out-of-pocket expenditures for medical consultations for people living with HIV in Senegal? An exploratory cross-sectional study.

Authors:  Bernard Taverne; Gabrièle Laborde-Balen; Khaly Diaw; Madjiguene Gueye; Ndeye-Ngone Have; Jean-Francois Etard; Khoudia Sow
Journal:  BMJ Open       Date:  2021-07-07       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.